SCHEMBL12204015

SCHEMBL12204015

COCCN(C)c1ccc(C(C)c2ccc(Cl)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 2/20 0.43
▸ DHFR P00374 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNB4 P30926 1/20 0.37
▸ CHRNA3 P32297 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ UTS2R Q9UKP6 2/20 0.36
▸ ADRB2 P07550 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ SLC6A2 P23975 2/20 0.35
▸ SLC6A4 P31645 2/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ ADRA2B P18089 1/20 0.35
▸ HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12229858 0.84 APP (0.33) —
SCHEMBL12204014 0.82 UTS2R (0.41) AOC3UTS2RADRB2LMNASMN1; SMN2
SCHEMBL14473433 0.82 USP1 (0.34) —
SCHEMBL18562081 0.79 BRAF (0.41) MEN1KMT2A
SCHEMBL20005026 0.78 KDM4C (0.43) MEN1KMT2ANPC1SMN1; SMN2
SCHEMBL16082898 0.76 EGFR (0.37) SMN1; SMN2
SCHEMBL27536583 0.75 FAAH (0.42) MEN1KMT2A
SCHEMBL27536584 0.75 ALDH1A1 (0.35) MEN1KMT2A
SCHEMBL12204160 0.74 ALDH1A1 (0.52) AOC3MEN1KMT2ANPC1POLB
SCHEMBL10216056 0.72 ALDH1A1 (0.44) AOC3LMNASMN1; SMN2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034949-B2 Pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-11 — — US disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same CNR1, CNR2, OPRD1 AOC3 1114/4885DHFR 913/4885MEN1 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback